Healthcare
Live Price
Offline$16.83
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Towa Pharmaceutical Co., Ltd. (TWAPF) is a Healthcare stock with a market cap of $194.94B and listed on OTC. The stock last traded around $16.83 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +13.9%, EPS growth of +17.4%, a dividend yield of 2.0%. What stands out right now is revenue +13.9%, EPS +17.4%, free cash flow +74.9% with operating margin 8.9% and ROIC 4.3%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 9.1 and price/sales 0.7. Stock Foundry combines TWAPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TWAPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TWAPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TWAPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$154.9B
-6.5% YoY
FY Net Income
$14.0B
-12.3% YoY
Free Cash Flow
$2.1B
-75.1% YoY
Revenue Growth
+13.9%
EPS Growth
+17.4%
Gross Margin
36.7%
Net Margin
7.9%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 259.6B | 227.9B | 208.9B | 165.6B | 154.9B |
| Gross Profit | 94.7B | 81.4B | 72.7B | 70.2B | 65.5B |
| Operating Income | 23.2B | 17.6B | 5.5B | 19.2B | 19.9B |
| EBITDA | 48.1B | 43.3B | 24.9B | 29.5B | 30.4B |
| Net Income | 19.0B | 16.2B | 2.2B | 15.9B | 14.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 45.5B | 29.6B | 24.3B | 32.8B | 22.9B |
| Total Assets | 470.8B | 430.7B | 371.3B | 329.9B | 245.7B |
| Total Liabilities | 299.2B | 274.8B | 234.5B | 197.8B | 129.1B |
| Shareholder Equity | 171.6B | 155.9B | 136.9B | 132.2B | 116.6B |
| Total Debt | 231.0B | 202.4B | 173.1B | 144.1B | 84.8B |
| Net Debt | 185.5B | 172.7B | 148.8B | 111.3B | 61.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12.0B
-45.7% YoY
Capital Expenditures
9.9B
+27.2% YoY
Free Cash Flow
2.1B
-75.1% YoY
Key ratios
Gross Margin
36.7%
Operating Margin
8.9%
Net Margin
7.9%
ROE
12.0%
Debt / Equity
1.23x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.